Sheena Jonathan sold $837K of NTRA

Sheena Jonathan sold 3,150 shares of Natera, Inc. (NTRA) at an average of $265.68 ($262.72–$268.39, $0.84M total) across 6 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Jul 16, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

Traders may monitor for patterns in insider activity, but this specific disclosure lacks new fundamentals and is unlikely to drive a durable repricing by itself.

02

Market read

A disclosed insider sale by a director under a 10b5-1 plan, with no accompanying company-specific news.

03

What to watch

The article does not state whether other insiders sold/bought around the same time, nor does it quantify total insider ownership changes beyond the post-transaction share count.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed after-hours on 2026-07-15, covering sales dated 2026-07-13.

Background

The article is an SEC Form 4 insider transaction for Natera, Inc., reported by a director and executed as an open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera director Sheena Jonathan sold about 3,150 shares in an open-market sale totaling $836,898.26 under a 10b5-1 plan.

Expected impact

Likely limited, short-lived impact; any reaction should fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the article provides no new guidance, contracts, or regulatory developments.

Market effects

Minimal. No sector-wide read-across is provided beyond a single-company insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, the transaction may reflect scheduled liquidity needs rather than bearish expectations, so any negative tape reaction could be overdone.

Key entities

  • Natera, Inc.

    Company whose director insider sale is disclosed via SEC Form 4.

  • Sheena Jonathan

    Director who sold shares totaling $836,898.26 across six trades on 2026-07-13.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.